natgillin/translations-raw huggingface dataset:
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins. 
68,7%, nefebrinsko specifične: 31,1%), 89,5% heparin, 78,7% zaviralce adrenergičnih receptorjev beta, 54,7% zaviralce ACE in 63 % statine.
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction. 
je večina bolnikov jemala ASA prvih nekaj dni po akutnem MI.
You should specifically tell your doctor if you take - oral anticoagulants, medicines used to reduce blood clotting, - a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, - heparin, or any other medicine used to reduce blood clotting. 
Podrobno morate obvestiti svojega zdravnika, če jemljete - peroralne koagulanse, zdravila, ki se uporabljajo za preprečevanje strjevanja krvi, - nesteroidna protivnetna zdravila, običajno za lajšanje bolečih in/ali vnetih sklepov ali mišic,
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis. 
zobca, visoka do nizka raven tveganja, diabetes, potreba po revaskularizaciji, spol, starost, itd), so skladni z rezultati primarne analize.
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors). 
Koristi, ki so jih opazili s klopidogrelom, so bile neodvisne od drugih akutnih in dolgotrajnih srčnožilnih terapij (kot je heparin /nizkomolekularni heparin, antagonisti glikoproteina IIb/IIIa, učinkovinami za zniževanje lipidov, zaviralci adrenergičnih receptorjev beta in zaviralci angiotenzinske konvertaze (ACEI)).
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, rash erythematous, urticaria, eczema, lichen planus 
(toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), angioedem, eritematozni izpuščaj, urtikarija, ekcem, lihen planus
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA groups, respectively). 
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve majhen in podoben v obeh skupinah (0,6-odstoten v skupini s klopidogrelom in ASA ter 0,5-odstoten v skupini s placebom in ASA).
If you experience prolonged bleeding when taking Clopidogrel Teva Generics B.V. 
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel Teva Generics B.V.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis 
(hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
Zlasti post hoc analiza podatkov 2172 bolnikov (17% celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2% zmanjšanje RT za sestavljen primarni opazovani dogodek (srčnožilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9% zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
CYP2C19 poor metaboliser status is associated with diminished response to clopidogrel. 
• Farmakogenetika Status slabega presnavljalca s CYP2C19 je povezan z manjšim odzivom na klopidogrel.
The incidence of severe cases was 1.4% for clopidogrel and 1.6% for ASA. 
Incidenca hujših primerov krvavitev je bila pri klopidogrelu 1,4%%, pri ASA pa1,6%%.
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2). 
Iz previdnosti naj sočasno ne bi uporabljali zdravil, ki zavirajo CYP2C19 (za seznam zaviralcev CYP2C19 glejte poglavje 4.5; glejte tudi poglavje 5.2).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]). 
Pri analizi podskupin glede na vključitveni pogoj (MI, ishemična kap in PAD) je bila korist (doseganje statistične značilnosti pri p = 0,003) največja pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi MI) (zmanjšanje RT: =23,7%; IZ: 8,9 do 36,2), in manjša (ni bila pomembno drugačna kot pri ASA) pri bolnikih s kapjo (zmanjšanje RT: 7,3%; IZ: -5,7 do 18,7 /p = 0,258/).
• Severe liver impairment. 
• Huda jetrna okvara.
If you become pregnant while taking Clopidogrel Teva Generics B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
• if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) - a recent serious injury - a recent surgery (including dental) - a planned surgery (including dental) in the next seven days 
- zdravstveno stanje s tveganjem za notranjo krvavitev (rana na želodcu), - krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih, organih ali sklepih vašega telesa), - nedavna huda poškodba, - nedavni kirurški poseg (tudi na zobeh),
As a precaution, concomitant use of omeprazole or esomeprozole should be discouraged (see section 4.4). 
Zaradi previdnosti se je treba izogniti sočasni uporabi omeprazola ali esomeprazola (glejte poglavje 4.4).
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy. 
(6,6%) bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
Rare side effect (affects 1 to 10 patients in 10,000): Vertigo. 
Redki neželeni učinki (pojavijo se pri 1 do 10 od 10.000 bolnikov): vrtoglavica.
Clopidogrel has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Klopidogrel nima ali ima zanemarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000 
Jedro tablete: mikrokristalna celuloza brezvodni koloidni silicijev dioksid krospovidon (vrsta A) makrogol 6000 hidrogenirano ricinusovo olje
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja bulozni dermatitis
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. 
Okvara jeter Po večkratnem odmerjanju 75 mg klopidogrela na dan 10 dni pri bolnikih s hudo okvaro jeter je bilo zavrtje z ADP izzvane agregacije trombocitov podobno kot pri zdravih preiskovancih.
If you take more Clopidogrel Teva Generics B.V. than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Zaradi povečanega tveganja za krvavitev se posvetujte s svojim zdravnikom ali z medicinskim osebjem na najbližjem bolnišničnem oddelku za nujno zdravniško pomoč.
The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1). 
ki bi bilo daljše od štirih tednov, v tem okviru niso preučevali (glejte poglavje 5.1).
In CURE, the major bleeding event rate for clopidogrel + ASA was dose-dependent on ASA (<100 mg: 2.6%; 100-200 mg: 3.5%; >200 mg: 4.9%) as was the major bleeding event rate for placebo + ASA (<100 mg: 2.0%; 100-200 mg: 2.3%; >200 mg: 4.0%).The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months (clopidogrel: 9.6%; placebo: 6.6%), 1-3 months (clopidogrel: 4.5%; placebo: 2.3%), 3-6 months (clopidogrel: 3.8%; placebo: 1.6%), 6-9 months (clopidogrel: 3.2%; placebo: 1.5%), 9-12 months (clopidogrel: 1.9%; placebo: 1.0%). 
Tveganje za krvavitve (življenje ogrožajoče, velike, manjše, druge) se je zmanjševalo med preizkušanjem: 0-1 meseca (klopidogrel: 9,6%%; placebo: 6,6%%), 1-3 mesecev (klopidogrel: 4,5%%; placebo: 2,3%%), 3-6 mesecev (klopidogrel: 3,8%%; placebo: 1,6%%), 6-9 mesecev (klopidogrel: 3,2%%; placebo: 1,5%%), 9-12 mesecev (klopidogrel: 1,9%%; placebo:
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively. 
22% (IZ: 8,6, 33,4), 32% (IZ: 12,8, 46,4), 4% (IZ: -26,9, 26,7), 6% (IZ: -33,5, 34,3) in 14% (IZ: -31,6,
− ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics. 
Akutni miokardni infarkt z elevacijo ST spojnice: klopidogrel je potrebno dajati v enkratnem dnevnem odmerku 75 mg, zdravljenje pa je potrebno začeti s 300 mg udarnim odmerkom v kombinaciji z ASA ter z ali brez uporabe trombolitikov.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28x1 film-coated tablets-calendar pack) 
PRETISNI OMOT (28x1 filmsko obložena tableta - koledarsko pakiranje)
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. 
Zavrta je tudi agregacija trombocitov, ki jo izzovejo drugi agonisti kot ADP, ker pride do blokade ojačenja trombocitne aktivacije s sproščenim ADP.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital, or oestrogen. 
Na farmakodinamiko klopidogrela tudi ni pomembno vplivalo sočasno jemanje fenobarbitala ali estrogena.
Several polymorphic CYP450 enzymes activate clopidogrel. 
Klopidogrel aktivira več polimorfnih encimov CYP450.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries. 
Primarni opazovani dogodek je bil opažen pri 15,0% bolnikov v skupini s klopidogrelom in 21¸7% bolnikov v skupini s placebom, kar predstavlja absolutno zmanjšanje za 6,7% in 36% zmanjšanje verjetnosti v prid klopidogrela (95% IZ od 24% do 47%; p<0,001) v glavnem zaradi zmanjšanja zaradi infarkta zamašenih arterij.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies. 
Bolniki so bili naključno razporejeni v skupino, ki je prejemala klopidogrel (začetni odmerek 300 mg, nato 75 mg/dan, n=6.259) ali skupino, ki je prejemala placebo (n=6.303), oboje prejeto v kombinaciji z ASA (75-325 mg enkrat na dan) in drugimi standardnimi terapijami.
Acute liver failure, hepatitis, abnormal liver function test 
žolčnika in žolčevodov akutna jetrna odpoved, hepatitis, nenormalni testi jetrne funkcije
− Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Pri bolnikih z akutnim koronarnim sindromom: Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg na dan, n=1.752) ali placebo (n=1.739), oboje v kombinaciji z ASA (150 mg do 325 mg kot udarni odmerek, nato 75 mg do 162 mg na dan), fibrinolitičnim sredstvom in po potrebi heparinom.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Teva Generics B.V. (4 tablets of 75 mg) once at the start of treatment. 
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja da enkrat 300 mg zdravila Klopidogrel Teva Generics B.V.
Very rare side effects (affects less than 1 patient in 10,000): Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in the way things taste. 
Zelo redki neželeni učinki (pojavijo se pri manj kot 1 od 10.000 bolnikov): zlatenica, huda bolečina v trebuhu z bolečino v hrbtu ali brez nje, zvišana telesna temperatura, težave pri dihanju, ki so včasih povezane s kašljem, splošne alergijske reakcije, oteklina v ustih, mehurji na koži, kožna alergija,
Other concomitant therapy: 
Sočasno zdravljenje z drugimi zdravili:
Each film-coated tablet contains 75 mg of clopidogrel (as hydrochloride). 
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki klopidogrelijevega klorida).
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebotreated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogreltreated group. 
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5%) v skupini zdravljeni s klopidogrelom in 1.187 (18,8%) v skupini s placebom, to je 14% zmanjšanje relativnega tveganja (95% IZ od 6% -21%, p=0,0005) za skupino,
The incidence of major bleeding was similar between groups (1.3% versus 1.1% for the clopidogrel + ASA and the placebo + ASA groups, respectively). 
Incidenca večjih krvavitev je bila v obeh skupinah podobna (1,3% v skupini s klopidogrelom in ASA ter 1,1% v skupini s placebom in ASA).
Clopidogrel should be given as a single daily dose of 75 mg with or without food. 
• Odrasli in starostniki Klopidogrel dajemo kot enkratni dnevni odmerek po 75 mg, s hrano ali brez nje.
- a proton pump inhibitor (e.g, omeprazole) for upset stomach, - fluconazole, voriconazole, ciprofloxacin, or chloramphenicol, medicines to treat bacterial and fungal infections, - cimetidine, medicine to treat upset stomach, - fluoxetine, fluvoxamine, or moclobemide, medicines to treat depression, - carbamazepine, or oxcarbazepine, medicines to treat some forms of epilepsy, - ticlopidine, other antiplatelet agent. 
- cimetidin, zdravilo za zdravljenje težav z želodcem, - fluoksetin, fluvoksamin ali moklobemid, zdravila za zdravljenje depresije, - karbamazepin ali oksakarbazepin, zdravila za zdravljenje nekaterih oblik epilepsije, - tiklopidin, druga antiagregacijska zdravila.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva Generics B.V.. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta,
- swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
- otekanje ust ali bolezni kože, kot so izpuščaj, srbenje in mehurji na koži kar so lahko znaki alergijske reakcije.
Gastrointestinal disorders 
Preiskave trombocitov
Metabolism 
Trombolitiki.
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge. 
28 dni oziroma do odpusta dobivali klopidogrel (75 mg na dan, n=22.961) ali placebo (n=22.891) v kombinaciji z ASA (162 mg na dan).
A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN
Common side effects (affects 1 to 10 patients in 100): Diarrhoea, abdominal pain, indigestion or heartburn. 
Pogosti neželeni učinki (pojavijo se pri 1 do 10 od 100 bolnikov): driska, bolečina v trebuhu, slaba prebava ali zgaga.
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event. 
(intention to treat analysis) so v skupini, ki je jemala klopidogrel, opazili 939 dogodkov, v skupini, ki je jemala ASA, pa 1.020 dogodkov (zmanjšanje relativnega tveganja /RT/: 8,7%%, 95-odstotni interval zaupanja /IZ/: 0,2 do 16,4; p = 0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 (IZ: 0 do 20) bolnikom.
You should take Clopidogrel Teva Generics B.V. for as long as your doctor continues to prescribe it. 
morate jemati, dokler vam ga vaš zdravnik predpisuje.
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). 
Če se med zdravljenjem pojavijo klinični simptomi, ki opozarjajo na možnost krvavitve, moramo zaradi tveganja pojava krvavitve in hematoloških neželenih učinkov pretehtati potrebo po določanju števila krvnih celic in/ali po drugih ustreznih preiskavah (glejte poglavje 4.8).
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =4.0%; CI: -22.5 to 11.7 [p=0.639]). 
Pri bolnikih, ki so bili v preizkušanje vključeni samo na podlagi nedavnega MI, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT: -4%%;
Some other medicines may influence the use of Clopidogrel Teva Generics B.V. or vice versa. 
Nekatera druga zdravila lahko vplivajo na jemanje zdravila Klopidogrel Teva Generics B.V.
In a crossover clinical study, clopidogrel (300-mg loading dose followed by 75 mg/day) alone and with omeprazole (80 mg at the same time as clopidogrel) were administered for 5 days. 
V navzkrižni klinični študiji so 5 dni uporabljali bodisi klopidogrel sam (polnilni odmerek 300 mg in potem 75 mg/dan) bodisi z omeprazolom (80 mg hkrati s klopidogrelom).
4.7 Effects on ability to drive and use machines 
vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
OPA/Al/PVC-Al blisters containing 28, 30, 50, 56, 84, 90 and 100 film-coated tablets or perforated unit dose blister containing 28x1, 28x1 (calendar pack), 30x1, 50x1, 56x1, 84x1, 90x1 and 100x1 film-coated tablets in a carton. 
OPA/Al/PVC-Al pretisni omoti , ki vsebujejo po 28, 30, 50, 56, 84, 90 in 100 filmsko obloženih tablet ali perforirani, enoodmerni pretisni omoti, ki vsebujejo po 28x1, 28x1 (koledarsko pakiranje), 30x1, 50x1, 56x1, 84x1, 90x1 in 100x1 filmsko obloženo tableto v škatli.
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension 
Žilne bolezni resne krvavitve, krvavitev operacijske rane, vaskulitis, hipotenzija
You have been prescribed Clopidogrel Teva Generics B.V. to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack). 
vam je predpisan za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate otrdele arterije (znano tudi kot ateroskleroza), in
Hydrogenated castor oil 
Vsebuje hidrogenirano ricinusovo olje.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel. 
Zanesljivih podatkov o farmakodinamskem medsebojnem delovanju klopidogrela in drugih zaviralcev protonske črpalke ni. Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 (razen cimetidina, ki je CYP2C19 inhibitor) ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
CYP2C19 Phenotype and Genotype Frequency Frequency (%) 
Pogostnost fenotipov in genotipov CYP2C19 Pogostnost
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28, 28x1, 30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90, 90x1, 100, 100x1 film-coated tablets) 
PRETISNI OMOT (28, 28x1, 30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90, 90x1, 100, 100x1 filmsko obložena tableta)
The exposure to the active metabolite of clopidogrel was decreased by 45% (Day 1) and 40% (Day 5) when clopidogrel and omeprazole were administered together. 
Če sta bila klopidogrel in omeprazol uporabljena skupaj, se je izpostavljenost aktivnemu presnovku klopidogrela zmanjšala za 45% (1. dan) oz. 40% (5. dan).
Recent ischaemic stroke 
Nedavna ishemična kap
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites. 
Absorpcija na podlagi presnovkov klopidrogela, izločenih s sečem, je najmanj 50%.
Intermediate metabolism: CYP2C19*1/*2 or *1/*3 
Obsežna prenova: CYP2C19*1/*1 Srednja presnova: CYP2C19*1/*2 ali *1/*3 Slaba presnova: CYP2C19*2/*2, *2/*3 ali
If you forget to take Clopidogrel Teva Generics B.V. 
Če ste pozabili vzeti zdravilo Klopidogrel Teva Generics B.V.
Do not use Clopidogrel Teva Generics B.V. after the expiry date which is stated on the carton and blister after EXP. 
ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Name and address of the manufacturer(s) responsible for batch release 
ZA SPROŠČANJE SERIJE Ime in naslov izdelovalca, odgovornega za sproščanje serije
Clopidogrel Teva Generics B.V. 75 mg film-coated tablets Clopidogrel 
75 mg filmsko obložene tablete klopidogrel
Boxes of 28, 30, 50, 56, 84, 90 or 100 film-coated tablets in blisters or boxes of 28x1, 28x1 (calendar pack), 30x1, 50x1, 56x1, 84x1, 90x1 and 100x1 film-coated tablets in perforated unit dose blisters are available. 
Na voljo so v škatli po 28, 30, 50, 56, 84, 90 ali 100 filmsko obloženih tablet v pretisnih omotih ali v škatli po 28x1, 28x1 (koledarsko pakiranje) 30x1, 50x1, 56x1, 84x1, 90x1 in 100x1 filmsko obložena tableta v preforiranih, enoodmernih pretisnih omotih.
CONDITIONS OF THE MARKETING AUTHORISATION 
POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM